Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: A comparison of data from two randomized, placebo-controlled studies

Clinical Drug Investigation

Volumn 31, Issue 4, 2011, Pages 247-255

  Hosoe, Motoi ^a   Woessner, Ralph ^b   Matsushima, Soichiro ^a   Lawrence, David ^c   Kramer, Benjamin ^b  

^a NOVARTIS PHARMA K K   (Japan)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Beta 2 adrenergic receptor agonists, therapeutic use; Chronic obstructive pulmonary disease, treatment; Ethnic groups; Indacaterol, pharmacokinetics; Indacaterol, therapeutic use; Research and development

Indexed keywords

INDACATEROL; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DEMOGRAPHY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG SAFETY; ETHNIC DIFFERENCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES;

EID: 79952410097     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11586520-000000000-00000     Document Type: Article

References (17)

1. Cazzola M, Matera MG, Lotvall J. Ultra long-acting b2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005; 14: 775-83 (Pubitemid 41030946)
2. Beier J, Chanez P, Martinot JB, et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily b2-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 2007; 20: 740-9 (Pubitemid 47446351)
3. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008; 102: 1033-44
4. Yasuda SU, Zhang L, Huang S-M. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008; 84: 417-23
5. Glasbrenner M, Rosenkranz G. A note on ethnic sensitivity studies. J Biopharm Stat 2006; 16: 15-23 (Pubitemid 43062289)
6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2009 [online]. Available from http://www.goldcopd.org [Accessed 2010 Jun 3]
7. Japanese Respiratory Society. Guideline for the diagnosis and treatment of COPD (2nd edition, 2009) [online]. Available from http://www.jrs.or.jp/ quicklink/glsm/guideline/nopass-pdf/copd-summary-e.pdf [Accessed 2010 Jun 3]
8. Bauwens O, Ninane V, Van de Maele B, et al. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin 2009; 25: 463-70
9. Kato M, Makita H, Uemura K, et al. Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: a randomized, double-blind, placebo-controlled trial. Allergol Int 2010; 59: 285-93
10. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2005 (based on an April 1998 NHLBI/WHO Workshop) [online]. Available from http://goldcopd.com [Accessed 2009 May 17]
11. Japanese Respiratory Society. Guideline for the diagnosis and treatment of COPD, 1st edition [in Japanese]. Tokyo: Japanese Respiratory Society, 2004
12. US Department of Health and Human Services, Food and Drug Administration, October 2005. Guidance for Industry. E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmicdrugs [online]. http://www.fda.gov/cder/guidance/6922fnl.pdf [Accessed 2009 May 17]
13. Lin Y-L, Chern H-D, Chu M-L. Taiwan's experience with the assessment of the acceptability of the extrapolation of foreign clinical data for registration purposes. Drug Inf J 2003; 37: 143-5 (Pubitemid 37305448)
14. Burroughs VJ, Randall WM, Richard AL. Racial and ethnic differences in response to medicine: towards individualized pharmaceutical treatment. JNatl Med Assoc 2002; 94: 1-26
15. Makita H, Nasuhara Y, Nagai K, et al. Characterization of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 2007; 62: 932-7 (Pubitemid 350084489)
16. Friedlander AL, David L, Liesel AD, et al. Phenotype of chronic obstructive pulmonary disease. COPD 2007; 4: 355-84 (Pubitemid 350135871)
17. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new oncedaily LABA, indacaterol, versus the twice-daily LABA, formoterol, in COPD. Thorax 2010; 65: 473-9